<ul>
<li>Antengene appointed Bing Hou as chief scientific officer on May 19, 2026, reporting to founder, chairman and CEO Jay Mei.     *      Hou will lead drug discovery, translational medicine, and chemistry, manufacturing and controls, with a mandate to deepen internal R&amp;D and build a next-generation pipeline.     *      He joined Antengene in 2019, most recently serving as vice president and head of discovery science and translational medicine, where he built the discovery organization and advanced internally discovered programs into clinical development.     *      Hou holds a PhD in biomedicine from the University of Leeds and has published in journals including Nature and Science Advances, with more than 40 patent applications. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Antengene Corporation Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605192000PR_NEWS_USPR_____CN62873) on May 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</li>
</ul>

588130

159892

<p>Antengene has appointed Bing Hou as chief scientific officer, effective May 19, 2026. He will oversee drug discovery and R&D efforts, reporting to CEO Jay Mei. Hou, who joined Antengene in 2019, previously served as vice president of discovery science. He holds a PhD in biomedicine and has over 40 patent applications.</p>

PUBT

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

iShares Global Healthcare

GF CSI HK Innovative Drugs Industry ETF(QDII)

ChinaAMC SSE Health Care ETF Initiating Fund

Penghua CSI HK Connect Health Care Composite ETF

Tianhong CNI BIOMEDICINE ETF

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

E Fund CSI 300 Health Care ETF

First Trust NYSE Arca Biotech Index Fd

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Health Care Select Sector SPDR

Guotai CSI Bio-medicine ETF

Invesco Nasdaq Biotechnology ETF

E Fund CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Southern Hang Seng Biotech ETF(QDII)

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

Bosera Hang Seng SCHK Innovative Drug Select ETF

iShares Biotechnology ETF

Huaan Hang Seng Biotech ETF

BlackRock, Inc.

VanEck Biotech ETF

VG Health

iShares US Pharma

Yinhua CSI Innovative Drugs Industry ETF

China Merchants CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

Bosera Hang Seng Health Care ETF(QDII)

ANTENGENE-B

Antengene appoints Bing Hou as chief scientific officer